You just read:

Astellas Announces Updated Data from the Phase 1/2 CHRYSALIS Trial for Gilteritinib (ASP2215) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

News provided by

Astellas Pharma US, Inc.

Dec 06, 2015, 04:30 ET